10-Q: Zymeworks Reports First Quarter 2024 Financial Results, Provides Business Update

Zymeworks reports a net loss of $31.7 million for the first quarter of 2024, with a decrease in revenue primarily due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.

Summary

• Zymeworks, a clinical-stage biopharmaceutical company, reported a net loss of $31.7 million for the three months ended March 31, 2024.
• The company's revenue decreased to $10.0 million, compared to $35.6 million for the same period in 2023, primarily due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.
• Research and development expenses decreased by $13.9 million to $32.0 million, mainly due to reduced zanidatamab program costs.
• General and administrative expenses decreased by $1.1 million to $15.8 million.
• The company's cash resources, including cash, cash equivalents, and marketable securities, totaled $420.5 million as of March 31, 2024.
• Zymeworks anticipates that its existing cash and cash equivalents and short-term investments will fund operating and capital expenditures for at least the next twelve months.
• The company expects to submit investigational new drug applications for ZW191 and ZW171 in 2024, and for ZW220 and ZW251 in 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is advancing its pipeline, the significant decrease in revenue and net loss, along with the deprioritization of a clinical trial, temper the positive aspects. The sentiment is neutral to slightly negative.

Positives

• The company has a strong cash position of $420.5 million, which is expected to fund operations for at least the next twelve months.
• Jazz Pharmaceuticals completed the BLA submission for zanidatamab in the U.S. and is progressing with the MAA submission in Europe.
• Zymeworks is advancing its preclinical pipeline with plans to submit IND applications for multiple candidates in the next two years.
• The company has multiple strategic partnerships that provide non-dilutive funding and potential future revenue streams.

Negatives

• The company reported a net loss of $31.7 million for the first quarter of 2024.
• Revenue decreased significantly due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.
• The company has an accumulated deficit of $709.1 million.
• The company has deprioritized the initiation of the planned Phase 2 study for zanidatamab zovodotin in combination with pembrolizumab in NSCLC and has paused recruitment of its Phase 1 clinical trial in Japan.

Risks

• The company's success is heavily reliant on the clinical development and commercialization of its product candidates, which are subject to regulatory and clinical trial risks.
• The company depends on its collaborative relationship with Jazz Pharmaceuticals for the development and commercialization of zanidatamab.
• The company relies on third-party manufacturers and service providers, which could lead to supply chain disruptions or delays.
• The company faces significant competition in the biopharmaceutical industry.
• The company may require substantial additional funding in the future, which may not be available on acceptable terms or at all.
• The company is subject to risks associated with conducting business internationally, including economic, political, and regulatory risks.
• The company is subject to risks associated with public health outbreaks and pandemics.

Future Outlook

Zymeworks anticipates that its existing cash and cash equivalents and short-term investments will fund operating and capital expenditures for at least the next twelve months. The company expects to submit investigational new drug applications for ZW191 and ZW171 in 2024, and for ZW220 and ZW251 in 2025.

Management Comments

• Jazz is targeting the pivotal Phase 3 top-line readout from the zanidatamab HERIZON-GEA-01 trial in late 2024.
• Jazz announced its intention to initiate a Phase 3 clinical trial, anticipated in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd).

Industry Context

The biopharmaceutical industry is highly competitive, with many companies developing treatments for cancer. Zymeworks is focused on developing novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases. The company's strategic partnerships and proprietary platforms are key to its competitive strategy.

Comparison to Industry Standards

• Zymeworks' decrease in revenue is largely due to the transfer of the zanidatamab program to Jazz, which is a strategic move to focus on its other pipeline candidates.
• The company's cash position of $420.5 million is relatively strong compared to other clinical-stage biopharmaceutical companies, providing a runway for continued development.
• The company's focus on novel ADC and multispecific antibody therapeutics aligns with current industry trends in oncology drug development.
• The company's pipeline of preclinical candidates, including ZW191, ZW171, ZW220, and ZW251, demonstrates a commitment to innovation and diversification.
• The company's reliance on strategic partnerships is a common practice in the biopharmaceutical industry, allowing for shared risk and resources.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, but reassured by the company's strong cash position and pipeline progress.
• Employees may be affected by the organizational changes and the transfer of personnel to Jazz Pharmaceuticals.
• Customers and strategic partners may be impacted by the company's focus on its preclinical pipeline and the transfer of the zanidatamab program.
• Creditors may be reassured by the company's strong cash position and ability to fund operations for at least the next twelve months.

Next Steps

• Submit investigational new drug applications for ZW191 and ZW171 in 2024.
• Submit investigational new drug applications for ZW220 and ZW251 in 2025.
• Jazz Pharmaceuticals to continue clinical development of zanidatamab, including a Phase 3 confirmatory trial for first-line treatment in BTC.
• Jazz Pharmaceuticals to submit a marketing authorization application to the European Medicines Agency for zanidatamab in BTC.

Key Dates

Keywords

Zymeworks, zanidatamab, biotherapeutics, clinical trials, oncology, antibody-drug conjugate, bispecific antibody, Jazz Pharmaceuticals, financial results, research and development